Stanley 2019 — Tesamorelin for NAFLD in HIV

The Lancet HIV·December 1, 2019

Takara L. Stanley, Janice H. Lee, Sara H. Paulsen, Steven K. Grinspoon, et al.

Summary

Tesamorelin reduced liver fat and prevented fibrosis progression in people with HIV and NAFLD, extending its relevance beyond visceral adipose tissue alone.

Study Details

Study Design

Randomized double-blind multicenter trial

Indication

Non-alcoholic fatty liver disease in people with HIV

Intervention

Tesamorelin vs placebo

Species

Human

Sample Size

61 subjects

Risk of Bias Assessment

Sponsor-supported; small disease-specific trial